該產品是本集團開發的全人源Ig G1單克隆抗體藥物，為司庫奇尤單抗注射液（ 可善挺® ）的 生物類似藥。可善挺®在中國獲批的適應症包括6歲及以上斑塊狀銀屑病、銀屑病關節炎、 強直性脊柱炎及化膿性汗腺炎，其療效與安全性已獲得廣泛認可。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 司庫奇尤單抗注射液III期臨床試驗獲得頂線分析數據 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 布 ， 本 公 司 附 屬 公 司 石 藥 集 團 巨 石 生 物 製 藥 有 限 公 司 開 發 的 司 庫 奇 尤 單 抗 注 射 液（「 該 產 品」）在用於治療中度至重度斑塊狀銀屑病的等效性III期臨床試驗中獲得頂線分析數據。 銀 屑 病 是 一 種 免 疫 相 關 的 慢 性 、 炎 症 性 、 系 統 性 疾 病 。 目 前 ， 中 國 約 有 超 700 萬 銀 屑 病 患 者。全人源白介素(IL) -1 ...

格隆汇12月18日丨新诺威(300765.SZ)公布，控股子公司石药集团巨石生物制药有限公司（简称"巨石生 物"）开发的司库奇尤单抗注射液于近日在 III 期临床试验中获得顶线分析数据。该产品是巨石生物开发 的全人源IgG1单克隆抗体药物，为可善挺?的生物类似药。可善挺?在中国获批的适应症包括6岁及以上 斑块状银屑病、银屑病关节炎、强直性脊柱炎及化脓性汗腺炎，其疗效与安全性已获得广泛认可。银屑 病是一种免疫相关的慢性、炎症性、系统性疾病，目前中国约有700万银屑病患者。全人源白介素 （IL）-17A主要由活化T细胞产生，是银屑病发病机制中的关键分子。司库奇尤单抗可特异性结合IL- 17A，阻断IL-17受体的信号传导，从而抑制银屑病炎症。 巨石生物遵循生物类似药的研究指导原则开展该产品的研发，并与可善挺?进行了"头对头"等效性研 究。该研究是一项多中心、随机、双盲、平行、阳性对照等效性Ⅲ期临床试验，旨在验证该产品与可善 挺?治疗中度至重度斑块状银屑病患者疗效的一致性。入组人群为中度至重度斑块状银屑病患者，按照 1:1比例随机分配至试验组（该产品）和对照组（可善挺）。主要研究终点为第12周达到银屑病皮损面 积和 ...

新诺威（300765）(300765.SZ)发布公告，公司的控股子公司石药集团巨石生物制药有限公司(简称"巨石 生物")开发的司库奇尤单抗注射液于近日在III期临床试验中获得顶线分析数据。 该产品是巨石生物开发的全人源IgG1单克隆抗体药物，为可善挺的生物类似药。可善挺在中国获批的 适应症包括6岁及以上斑块状银屑病、银屑病关节炎、强直性脊柱炎及化脓性汗腺炎，其疗效与安全性 已获得广泛认可。 该项关键研究已达到预设主要终点，并取得积极的顶线结果，统计分析表明，该产品与可善挺具有临床 等效性，且安全性良好，未出现新的或非预期的安全性信号，有望能满足患者长期用药的安全性需求。 有关详细数据将于后续学术会议及期刊上发布。 ...

该产品是巨石生物开发的全人源IgG1单克隆抗体药物，为可善挺®的生物类似药。可善挺®在中国获批 的适应症包括6岁及以上斑块状银屑病、银屑病关节炎、强直性脊柱炎及化脓性汗腺炎，其疗效与安全 性已获得广泛认可。 智通财经APP讯，新诺威(300765.SZ)发布公告，公司的控股子公司石药集团巨石生物制药有限公司(简 称"巨石生物")开发的司库奇尤单抗注射液于近日在III期临床试验中获得顶线分析数据。 该项关键研究已达到预设主要终点，并取得积极的顶线结果，统计分析表明，该产品与可善挺®具有临 床等效性，且安全性良好，未出现新的或非预期的安全性信号，有望能满足患者长期用药的安全性需 求。有关详细数据将于后续学术会议及期刊上发布。 ...

Core Viewpoint - The announcement from XinNuoWei indicates that its subsidiary, Jushi Biopharma, has achieved top-line analysis data from the Phase III clinical trial of its drug, Secukinumab injection, which is a fully human IgG1 monoclonal antibody and a biosimilar to Cosentyx [1] Group 1: Product Development - Secukinumab is developed as a biosimilar to Cosentyx, which has been approved in China for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa [1] - The efficacy and safety of Cosentyx have been widely recognized in the medical community [1] Group 2: Market Context - Psoriasis is a chronic, inflammatory, systemic disease related to the immune system, with approximately 7 million patients suffering from psoriasis in China [1] - Interleukin (IL)-17A, primarily produced by activated T cells, is a key molecule in the pathogenesis of psoriasis [1] Group 3: Mechanism of Action - Secukinumab specifically binds to IL-17A, blocking the signaling of the IL-17 receptor, thereby inhibiting the inflammation associated with psoriasis [1]

Summary of Alvotech Conference Call Company Overview - Alvotech is a biosimilar company founded in 2013, aiming to become a leading player in the global biosimilar market with a focus on R&D, manufacturing, and marketing reach [2][3] - The company has invested approximately $2 billion since its inception and has around 30 products in its development pipeline [2][3] Industry and Market Position - Alvotech has launched five products outside the U.S. and plans to launch its first commercial product in the U.S. market in 2024 [3] - The company has experienced a compound annual growth rate (CAGR) of 74% from 2021 to 2026 [3] - Alvotech has established partnerships with 19 commercial partners, which contribute to R&D funding through milestone payments [4] Financial Performance - For the first nine months of 2025, Alvotech reported a revenue growth of 24%, with a gross margin of 59% [18][19] - EBITDA for the same period was at 16%, impacted by higher R&D and G&A costs [19] - The company has provided guidance for 2025, projecting revenues between $570 million and $600 million, and EBITDA between $130 million and $150 million, indicating a 19% year-on-year revenue increase and a 30% improvement in EBITDA [21][22] - For 2026, Alvotech anticipates revenues of $650 million to $700 million and adjusted EBITDA of $180 million to $220 million [22] Product Pipeline and Approvals - Alvotech has received complete response letters (CRLs) for three of its four Biologics License Applications (BLAs) submitted in Q4 2024, including biosimilars to Simponi and Eylea [9][10] - The company is optimistic about resolving outstanding issues with the FDA and is focused on scaling up and launching recently approved products in Europe and Japan [10][11] - The total addressable market for recently approved products outside the U.S. is approximately $3 billion [12] Regulatory and Compliance - Alvotech has undergone multiple inspections by regulatory authorities, including the FDA, EMA, and PMDA, with minor observations noted [6][31] - The company has implemented close to 200 corrective and preventive actions (CAPAs) to address FDA concerns and is working towards resolving issues related to product quality complaints and environmental monitoring [7][30][31] Strategic Focus - Alvotech's strategic focus for the next 18 months includes advancing its pipeline, supporting global product launches, and diversifying revenue across geographies and products [23] - The company plans to invest around $250 million in R&D for 2026 to maintain a strong biosimilar pipeline [23] Conclusion - Alvotech is positioned for significant growth in the biosimilar market, with a robust pipeline, strong partnerships, and a clear strategic focus on execution and market expansion [23][35]

Core Viewpoint - Fuhong Hanlin (复宏汉霖) is positioned as a leading player in the biosimilar drug market in China, focusing on hematological malignancies, solid tumors, and autoimmune diseases, with a strong emphasis on international collaboration and product commercialization [1][2] Group 1: Business Performance - In 2023, the company achieved profitability with projected revenue of 5.724 billion yuan in 2024, representing a 6% year-on-year growth, and a net profit of 815 million yuan, reflecting a 50% increase compared to the previous year [2] - The company is expected to enter a high-growth phase in overseas business by 2025, with overseas product profits projected to grow over 200% in the first half of 2025 [2] Group 2: Product Pipeline and R&D - HLX43, a potential BICPD-L1ADC, is under clinical development for multiple indications including lung cancer and gastric cancer, showing significant efficacy in clinical trials with an overall response rate (ORR) of 33.3% for squamous NSCLC and 48.6% for non-squamous NSCLC [3] - HLX22, in combination with trastuzumab, has shown improved efficacy and safety in treating HER2-positive gastric/gastroesophageal junction cancer, with ongoing global Phase III trials [3] - The company is also advancing the development of Surulitinib, which aims to replace postoperative chemotherapy in gastric cancer with immunotherapy, having met primary clinical endpoints [3] Group 3: Market Strategy and Valuation - The company has established a global presence with its biosimilar products, which are key drivers of revenue growth, and is considering implementing full circulation of H-shares to enhance liquidity [4] - The projected net profits for 2025-2027 are estimated at 823 million, 744 million, and 1.129 billion yuan respectively, with corresponding price-to-earnings ratios of 39, 43, and 28, suggesting a total market valuation between 52.1 billion and 67.9 billion yuan [4]

智通财经APP讯，华兰生物(002007.SZ)发布公告，近日，公司参股公司华兰基因工程有限公司(以下简 称"基因公司")收到国家药品监督管理局签发的地舒单抗注射液境内生产药品注册上市许可申请《受理 通知书》(受理号：CXSS2500138)。 目前国内已有江苏泰康生物医药有限公司、齐鲁制药有限公司、山东博安生物技术股份有限公司、康宁 杰瑞(吉林)生物科技有限公司四家公司的地舒单抗注射液获批上市，若基因公司获批上市，将丰富基因 公司的产品梯队，为基因公司增加新的利润增长点。 地舒单抗是一种人源化单克隆抗体(IgG2型)，通过特异性靶向核因子κB受体活化因子配体(RANKL)发 挥作用。RANKL是破骨细胞形成、发挥功能和存活所必需的关键因子。恶性肿瘤骨转移常导致骨溶解 性破坏，引发骨痛、病理性骨折、脊髓压迫、高钙血症等骨相关事件，严重影响患者生活质量和生存预 后。地舒单抗通过抑制RANKL，强效抑制破骨细胞介导的骨吸收和骨破坏，从而有效预防和延迟上述 骨相关事件的发生，是临床重要的肿瘤支持治疗药物。 公司研发的地舒单抗注射液为生物类似药。其原研产品由安进公司开发，已在全球多个国家及地区获批 上市，用于治疗骨质 ...

目前国内已有江苏泰康生物医药有限公司、齐鲁制药有限公司、山东博安生物技术股份有限公司、康宁 杰瑞(吉林)生物科技有限公司四家公司的地舒单抗注射液获批上市，若基因公司获批上市，将丰富基因 公司的产品梯队，为基因公司增加新的利润增长点。 地舒单抗是一种人源化单克隆抗体(IgG2型)，通过特异性靶向核因子κB受体活化因子配体(RANKL)发 挥作用。RANKL是破骨细胞形成、发挥功能和存活所必需的关键因子。恶性肿瘤骨转移常导致骨溶解 性破坏，引发骨痛、病理性骨折、脊髓压迫、高钙血症等骨相关事件，严重影响患者生活质量和生存预 后。地舒单抗通过抑制RANKL，强效抑制破骨细胞介导的骨吸收和骨破坏，从而有效预防和延迟上述 骨相关事件的发生，是临床重要的肿瘤支持治疗药物。 格隆汇12月15日丨华兰生物(002007.SZ)公布，近日，公司参股公司华兰基因工程有限公司(以下简称"基 因公司")收到国家药品监督管理局签发的地舒单抗注射液境内生产药品注册上市许可申请《受理通知 书》(受理号：CXSS2500138)。 公司研发的地舒单抗注射液为生物类似药。其原研产品由安进公司开发，已在全球多个国家及地区获批 上市，用于治疗骨质疏 ...

BAT2506(戈利木单抗注射液)的原研药为美国强生公司的Simponi® (欣普尼®)。根据强生公司2024年年 度报告，Simponi®2024年在全球的销售额为21.90亿美元。 BAT2506是百奥泰根据中国国家药品监督管理局(以下简称"NMPA")、美国食品药品监督管理局(以下简 称"FDA")、EMA生物类似药相关指导原则开发的戈利木单抗生物类似药。戈利木单抗是靶向TNF-α的 抗体，能够以高亲和力特异性地结合可溶性及跨膜的人TNF-α，阻断TNF-α与其受体TNFR结合，从而 抑制TNF-α的活性。 智通财经APP讯，百奥泰(688177.SH)发布公告，公司于近日收到了欧洲药品管理局(以下简称"EMA")的 通知，Gotenfia®(BAT2506，戈利木单抗注射液)获得EMA人用药品委员会(以下简称"CHMP")积极意 见。 CHMP建议欧盟委员会(EC)批准Gotenfia®上市，用于治疗类风湿关节炎，幼年特发性关节炎，银 屑病关节炎，中轴型脊柱关节炎，溃疡性结肠炎。 ...